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Am J Geriatr PsBackground: Delirium is a profound neuropsychiatric disturbance precipitated by
acute illness. Although dementia is the major risk factor this has typically been
considered a binary quantity (i.e., cognitively impaired versus cognitively normal)
with respect to delirium risk. We used humans and mice to address the hypothesis
that the severity of underlying neurodegenerative changes and/or cognitive impair-
ment progressively alters delirium risk. Methods: Humans in a population-based
longitudinal study, Vantaa 85þ, were followed for incident delirium. Odds for
reporting delirium at follow-up (outcome) were modeled using random-effects lo-
gistic regression, where prior cognitive impairment measured by Mini-Mental State
Exam (MMSE) (exposure) was considered. To address whether underlying neurode-
generative pathology increased susceptibility to acute cognitive change, mice at three
stages of neurodegenerative disease progression (ME7 model of neurodegeneration:
controls, 12 weeks, and 16 weeks) were assessed for acute cognitive dysfunction upon
systemic inﬂammation induced by bacterial lipopolysaccharide (LPS; 100 mg/kg).
Synaptic and axonal correlates of susceptibility to acute dysfunction were assessed
using immunohistochemistry. Results: In the Vantaa cohort, 465 persons (88.4  2.8
years) completed MMSE at baseline. For every MMSE point lost, risk of incident
delirium increased by 5% (p ¼ 0.02). LPS precipitated severe and ﬂuctuating cogni-
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Dementia Severity and Delirium Susceptibilityand controls, respectively. This was associated with progressive thalamic synaptic loss
and axonal pathology. Conclusion: A human population-based cohort with graded
severity of existing cognitive impairment and a mouse model with progressing
neurodegeneration both indicate that the risk of delirium increases with greater
severity of pre-existing cognitive impairment and neuropathology. (Am J Geriatr
Psychiatry 2015; 23:403e415)
Key Words: Delirium, dementia, neurodegeneration, neuropathology, synaptic,
axonal, thalamus, hippocampus, basal forebrain, ageing, cognitive decline, systemic,
inﬂammation, susceptibility, neuroinﬂammationelirium is a severe neuropsychiatric syndromeDcharacterized by acute cognitive deﬁcits and
inattention arising as a consequence of generalized
illness.1,2 It affects 10%e31% of older hospitalized
patients.3 Even higher prevalence has been reported
in settings associated with frailty (e.g., nursing
homes) or critical illness (e.g., intensive care units).4
As well as being profoundly distressing for patients,
relatives, and care staff,5 delirium is associated with
multiple poor outcomes: higher mortality, longer
hospital stay, and increased institutionalization.6,7
Dementia is a strong risk factor for developing
delirium,8 but the pathophysiology of this relationship
is not well established. Part of the difﬁculty in investi-
gating this in clinical samples is disentangling biolog-
ical andneuropsychiatric constructs related todelirium
(i.e., the acute precipitating disturbance) from the un-
derlying dementia (i.e., the chronic predisposition).
Hospital studies have usually relied on duration of
dementia diagnosis9 or informant scales (e.g., Infor-
mant Questionnaire on Cognitive Decline in the
Elderly or informant component of the Clinical De-
mentia Rating Scale) as ways of quantifying pre-
existing cognitive deﬁcits.10,11 Though these studies
have reported that deliriumwasmore likely in persons
with apparently more severe prior cognitive impair-
ments, it is difﬁcult to be conclusive about the reli-
ability of such retrospectivemeasures.Oneprospective
study in hospitalized patients showed that severity of
dementia progressively increases delirium risk.12
Separately capturing pre-existing cognitive func-
tion from incident delirium is heuristically (and
probably mechanistically) important, but the ability
to do this is limited in hospital samples for the rea-
sons outlined above. Here, we present two different
approaches (with different strengths and limitations)
that together may offer new perspectives. Firstly, weuse observational data from an epidemiologic cohort
study, where the risk of incident delirium can be
more reliably related to baseline cognitive function.
This generates hypotheses that can then be tested in
an experimental mouse model in which pre-existing
cognition and pathology can be controlled more
precisely. Interrogation of the contribution of speciﬁc
features of neurodegenerative pathology to cognitive
frailty may add to understanding the basis of
delirium risk associated with prior cognitive impair-
ment. Although neither analytic method can directly
demonstrate causation, there may be an argument for
a degree of coherence between the two approaches.
We hypothesized that severity of pre-existing brain
dysfunction progressively increases delirium risk and
wanted to investigate this prospectively. We
approached this by considering older humans from a
population-based cohort13,14 who had been assessed
with the Mini-Mental State Examination (MMSE).15
In parallel, we tested the hypothesis that severity of
underlying neurodegenerative pathology would
predispose to acute cognitive deﬁcits using mice with
none, intermediate, or severe neurodegenerative pa-
thology upon challenging them with systemic
inﬂammation or vehicle control (Table 1). We pre-
dicted increased susceptibility to acute dysfunction
even before disease-associated cognitive impairment
had emerged. We assessed the incidence of delirium
in humans and delirium-like cognitive dysfunction in
mice at follow-up.
The ﬁndings of this investigation would provide
important information on severity of cognitive
decline as a graded risk factor in a true representative
elderly population and a possible validation of a
small animal model for delirium pathophysiology
research. The overall purpose of these analyses is to
broaden the methods available for addressing theAm J Geriatr Psychiatry 23:4, April 2015
Davis et al.clinical problem of predisposing cognitive impair-
ment and its relationship to delirium risk.METHODS
See the Supplementary Appendix (available on-
line) for complete description of the methods.
Epidemiological Model (Human)
The Vantaa 85þ Study methods have been reported
previously.16 All individuals aged 85 years residing in
the city of Vantaa were invited to participate, with 553
persons recruited (92% of those eligible). Cognitive
function was simultaneously assessed by two neurol-
ogists at baseline and at four follow-up waves (3, 5, 8,
and 10 years). Dementia diagnoses were based on the
Diagnostic and Statistical Manual of Mental Disorders,
Third edition, Revised (DSM-III-R).17
The method for incident delirium ascertainment
has been described.13,14 At each Vantaa interview, the
examining neurologists assessed participants and
informant(s) for a history of any episodes of delirium,
with reference to a checklist of DSM-III-R criteria
for delirium diagnosis. The reported history and
number of episodes of delirium were corroborated
with hospital case notes that were available at the
time of assessment. Accordingly, delirium history
was retrospectively derived from multiple sources,
and the overall diagnosis accepted if the examining
neurologists judged that there was sufﬁcient evi-
dence from participant and informant recall and/or
indication in the medical notes.
Experimental Mouse (Model)
An experimental mouse model was used to test the
hypothesis that more severe underlying pathology
wouldprogressively increase the risk of acute cognitive
impairment upon systemic inﬂammatory challenge.
The ME7 prion mouse model is a well-established
model of chronic neurodegeneration that leads to
progressive synaptic loss, amyloid deposition, micro-
gliosis, and robust neuronal loss with learning and
memory deﬁcits.18,19 The three experimental groups
were as follows: mice injected with: (1) sham control
substance (normal brain homogenate; NBH); (2) prion-
infected brain homogenate (ME7 strain) surviving for
12 weeks to induce relatively selective hippocampalAm J Geriatr Psychiatry 23:4, April 2015synaptic loss; or (3) surviving for 16 weeks to induce
severe hippocampal and thalamic synaptic/neurode-
generative pathology. These three categories (NBH,
12w ME7, 16w ME7) represent ordered grades of pre-
existing neuropathology, but signiﬁcantly all precede
robust neuronal loss and major cognitive impairment.
Each group was then injected intraperitoneally with
either: (1) a low dose of lipopolysaccharide (LPS, 100
mg/kg), to mimic Gram-negative bacterial infection; or
(2) sterile saline, as a control. All experiments were
performed in compliance with the Cruelty to Animals
Act (1876) and the European Community Directive,
86/609/EEC.
Murine Cognitive Function. Cognitive function
was assessed using T-maze alternation. This task,
which requires attention to the maze arm initially
visited, retention of this information for the
25-second intra-trial interval, and execution of the
opposite turn to escape upon re-exposure to the
maze, has been described in detail.20 Deﬁcits on this
task may reﬂect inability to modulate the amount of
attention paid to recently experienced stimuli21,22 and
thus could potentially be related to the acute, ﬂuc-
tuating inattention and other cognitive deﬁcits seen
in delirium precipitated by a general medical condi-
tion (Table 1). Animals were trained (10 trials daily)
and those achieving a criterion of 70% or greater
alternation for 2 or more consecutive days were
challenged with LPS or saline. Animals were tested
every 20 minutes (3e9 hours post-LPS, 15 trials).
Experiments were performed in Oxford and Dublin,
by four different blinded experimenters to ensure
robustness and reproducibility. Chance responding
in this maze is 50% alternation and “acute impair-
ment” was deﬁned as 3 out of 5 correct in two or
more blocks or 2 or fewer out of 5 correct in any one
block. Differences in incidence, so deﬁned, between
groups were assessed using Fisher’s exact test.
Neuropathology. Mouse brains were wax-
embedded and sectioned (10 mm). To demonstrate
the relevant neuropathology, these were labeled with
antibodies against synaptophysin (synaptic density
marker) and neuroﬁlament heavy chain and amyloid
precursor protein (axonal damage markers). Sections
were photographed and synaptic density and axonal
pathology were recorded in the hippocampus and
posterior nuclei of the thalamus. Antibody labelling
was quantiﬁed by standardized methods (detailed in
Supplementary Material; available online).405
TABLE 1. Comparison of Animal and Population Study
Designs
Mouse (N)
Population
Samples (N)
Group NBH (46) MMSE score,
range 0e30 (468)ME7 12w (56)
ME7 16w (95)
Components
of outcome
assessed
Acute change,
ﬂuctuation
Acute change, ﬂuctuation
Impaired working
memory/attention
Inattention, cognition
Induced by LPS General medical
precipitant
Notes: NBH: normal brain homogenate control mice; ME7: prion;
MMSE: Mini-Mental State Examination.
TABLE 2. Logistic Regression Model Showing Odds of
Incident Delirium in Relation to Baseline Cognitive
Function
OR 95% CI p Value*
MMSE, per point 0.95 (0.92e0.99) 0.018
Age, per year 1.08 (1.00e1.18) 0.056
Sex, women cf. men 2.36 (1.03e5.40) 0.037
Comorbidity score 1.04 (0.90e1.19) 0.636
Notes: N ¼ 468 in 257 clusters. Goodness of ﬁt for model
residuals p ¼ 0.053 (Pearson c2 ¼ 426.77). *2-tailed p value used in
testing the null hypothesis that the coefﬁcient (parameter) is 0,
Wald c2 for 4 degrees of freedom ¼ 20.72. MMSE: Mini-Mental
Status Examination.
Dementia Severity and Delirium SusceptibilityStatistical Analyses
Epidemiology. Odds for reporting delirium at
follow-up (outcome) were modeled using random-
effects logistic regression, adjusting for age, sex, and
co-morbidity score based on the Charlson Index.23
Participants assessed in multiple waves were able
to contribute to the model for each observation, and
robust standard errors were estimated to account for
the clustered nature of these data. Time-in-study was
used as the time metric and covariance matrices were
unstructured.
In the majority of studies, the analytic properties of
the MMSE are often limited by ceiling effects that
result in highly skewed distributions. In our popu-
lation of older individuals (mean age 88 years),
however, the mean MMSE score (19.9) is very close to
the median (21), so the assumptions hold for the
Gaussian distribution required for modeling the
MMSE as a continuous parameter (Supplementary
Fig. 1; available online). Formal post-estimation
tests of goodness-of-ﬁt (Hosmer-Lemeshow) were
applied to check any violation of assumptions.
Experimental Model.
Cognitive function. The number of correct turns,
scored overﬁve trials, was considered as count data for
each time point during the experiment,with a random-
intercept multilevel Poisson model with indicator
variables ﬁtted for each time point. The number of
correct turns was speciﬁed as the outcome, and
experimental category (NBH, 12wME7, 16wME7) and
challenge (saline or LPS) as exposures along with any
interactions. The time points compared were between
baseline, and challenge (3e5, 5e7, 7e9 hours) and406recovery (22, 24 hours) periods, respectively. The
reference category was the average performance of
NBH mice at baseline (i.e., 24 and 22 hours before
LPS or saline), allowing comparisons to be made both
within and between groups. Fluctuation about the
meanperformancepost-acute challengewas calculated
for each individual animal. A score of 60, 80, 60 (mean:
66.7) is given an index of 6.7þ 13.3þ 6.7¼ 26.7, and 40,
80, 60 (mean: 60) is given 20þ 20þ 0¼ 40. Differences
in ﬂuctuation between experimental groups were
assessed using the Mann-Whitney test.
Pathology. Synaptophysin density and axonal
varicosities in ME7 and NBH animals (12 and 16
weeks) were compared by one-way analysis of vari-
ance (ANOVA) with Bonferroni corrections for post
hoc pairwise comparisons.RESULTS
Epidemiology
At baseline, 465 (84%) individuals had a completed
MMSE. Mean MMSE was 19.9 (SD: 7.0) points
(normal distributions shown in Supplementary Fig. 1;
available online), and mean age was 88.4 years (SD:
2.8). Women made up 364 of 465 (78%) of the cohort.
Follow-up data on delirium incidence was available
in 272, 153, 49, and 19 persons at 3, 5, 8, and 10 years,
respectively.
In total, 81 episodes of delirium were recorded at
follow-up. Table 2 reports the odds of incident
delirium as a function of baseline cognition; Figure 1
shows the probability of delirium over the range
of observed MMSE scores. For every MMSE point
lost, the risk of incident delirium increased by 5%Am J Geriatr Psychiatry 23:4, April 2015
FIGURE 1. Delirium risk in relation to prior MMSE. The
probability of delirium is plotted against previous
MMSE score, where each point is an observation of
delirium risk at follow-up. The model-predicted
coefﬁcient for delirium risk is described as a
straight line with a negative slope, showing an
inverse relationship.
TABLE 3. The Effect of Missing MMSE at Baseline
(Unclassiﬁable Participants) on Delirium Outcomes
OR 95% CI p value*
MMSE, per point 0.965 (0.933e0.998) 0.036
Age, per year 1.073 (0.988e1.167) 0.093
Sex, women cf. men 2.211 (1.003e4.877) 0.049
Comorbidity score 1.029 (0.893e1.185) 0.693
Notes: Logistic regression model showing odds of incident
delirium according to baseline cognitive function, including par-
ticipants with incomplete MMSE assessments, where this was
imputed as lowest score (MMSE ¼ 0). N ¼ 492 in 237 clusters.
Goodness of ﬁt for model residuals p ¼ 0.085 (Pearson c2 ¼
444.55). *2-tailed p value used in testing the null hypothesis that the
coefﬁcient (parameter) is 0, Wald c2 for 4 degrees of freedom ¼
17.97. MMSE: Mini-Mental Status Examination.
Davis et al.(p ¼ 0.02). For example, the probability of incident
delirium at follow-up for an 85-yearold man with
MMSE ¼ 28 points at baseline would be 0.12, rising
to 0.29 for an equivalent individual with an MMSE
score of 10 points at baseline. Co-morbidity score
did not inﬂuence likelihood of incident delirium
(p ¼ 0.63). Goodness-of-ﬁt testing showed no prob-
lems with model calibration.
Random-effects models account for data missing at
random. However, the 16% of baseline assessments
with incomplete MMSE are likely to be non-random.
Indeed, previous analyses showed this group to have
a risk of delirium similar to those with MMSE scores
in range less than 22 points (data not shown).
Nonetheless, a sensitivity analysis, whereby missing
MMSE scores were assigned an imputed value of
0 did not signiﬁcantly change the estimated param-
eters or conclusions (Table 3).Experimental Model
Acute Cognitive Dysfunction in Mice. Animals
challenged with LPS display signiﬁcantly lower
arousal and marked hypoactivity (SupplementaryAm J Geriatr Psychiatry 23:4, April 2015Video 1; available online). Figure 2 shows perfor-
mance of NBH and 12w and 16w ME7 mice over time
on the T-maze alternation task during LPS or saline
challenge. Although still greater than or equal to 80%,
baseline performance was signiﬁcantly lower in 16w
ME7 than in NBH mice (relative risk [RR] for errors:
2.11, 95% conﬁdence interval [CI] 1.43 to 3.13,
p <0.01, Supplementary Tables 1, 2; available online).
ME7 12w were not signiﬁcantly cognitively impaired
with respect to NBH mice. We hypothesized that
susceptibility to an acute stressor would increase
with progressing disease (i.e., 16w > 12w > NBH).
Testing an interaction between LPS challenge and
disease stage demonstrated a difference in magnitude
of LPS effect in each of the three categories (p <0.01,
Supplementary Table 2; available online).
Deﬁning a deﬁcit as less than or equal to 60%
alternation (i.e., 3/5 correct trials) in at least two
blocks on the treatment day or less than or equal to
40% (2/5 correct trials) in any one block, LPS pro-
duces impairment in fewer than 4% of normal ani-
mals, in 36% of 12w animals, and in 77% of 16w
animals. Thus, incidence of acute deﬁcits increases
with progressing underlying pathology (Fisher’s
exact test, p <0.01). Importantly, susceptibility to
acute disruption was present before baseline cogni-
tive differences emerged (i.e., at 12w).
When challenged with LPS there was no deﬁcit in
normal (NBH) mice compared with saline challenge
(errors at 3 hrs RR: 1.1 [p ¼ 0.74]; at 5 hrs RR: 0.8 [p ¼
0.35], at 7hrs RR: 0.6 [p¼ 0.12], Supplementary Table 3;
available online). The same LPS challenge produced a
transient deﬁcit in function in 12-week ME7 mice (er-
rors at 3 hrs RR: 1.8 [p ¼ 0.02], recovering by 5 hrs)407
FIGURE 2. Acute cognitive impairments induced by LPS are more severe in animals with more advanced neurodegenerative disease.
Performance of NBH (normal) mice, ME7 animals 12 weeks post-inoculation, or ME7 animals 16 weeks post-inoculation
upon challenge with saline or LPS (100 mg/kg), plotted with intervals showing the standard error of the mean. Criterion
baseline performance (‡70%) was ascertained for all challenged animals, and these were then tested 15 times (every 20
minutes for >5 hours: 3he9h post LPS) post-challenge as well as for 10 further trials 24 hours post-challenge. Statistically
signiﬁcantly different RR for errors are denoted by *p <0.05 and **p <0.01.
FIGURE 3. Systemic inﬂammation induces ﬂuctuating cognitive deﬁcits only in animals with existing neurodegenerative disease.
[A] Individual trajectories of performance in mice given LPS challenge, given in each experimental group. Plots are
jittered on the y-axis to distinguish overlapping plots. [B] Fluctuation about the mean correct performance (% trials)
according to experimental group. NBH normal brain homogenate (controls), 12w ME7 mice, and 16w ME7 mice. Mann-
Whitney: NBH-LPS versus NBH-saline, p [ 0.16; ME7 12w-saline versus ME7 12w-LPS, p [ 0.03 (denoted *); ME7 16w
saline versus ME7 16w-LPS, p <0.001 (denoted ***).
Dementia Severity and Delirium Susceptibilitywhereas a prolonged and increased deﬁcit is seen in
16-week ME7mice (errors at 3 hrs RR: 2.1 [p<0.01]; at
5 hrs RR: 2.4 [p <0.01]; at 7 hrs RR 2.2 [p <0.01],
Supplementary Table 5; available online).
The trajectory of each individual LPS-treated ani-
mal is shown in Figure 3, according to experimental
category. Performance in NBH was generally over
80% and decreases to 60% were not sustained for
more than one block. Impairments were more severe
and sustained in ME7 mice. Troughs in T-maze per-
formance were most evident in 16w ME7 mice and408could occur in any or all of the post-LPS trial blocks.
Therefore cognitive dysfunction ﬂuctuates with time.
Figure 3B shows the median ﬂuctuation about the
mean, which represents the distance from the mean
post-LPS performance of each individual animal for
each block of 5 trials post-challenge (see methods).
LPS induced statistically signiﬁcant ﬂuctuation in-
creases in 12w ME7 animals (Mann-Whitney,
z ¼ 2.22, p ¼ 0.03) and 16w ME7 animals
(z ¼ 4.02, p <0.001), but not in NBH animals
(z ¼ 1.4 p ¼ 0.16).Am J Geriatr Psychiatry 23:4, April 2015
FIGURE 4. Synaptic integrity deteriorates as a function of disease progression. Formalin ﬁxed, parafﬁn-embedded brains from NBH
and ME7 animals, at 12 and 16 weeks post-inoculation, were sectioned (10 mm) and labelled with antibodies against
synaptophysin (Sy38). [AeC] Gross view of hippocampus of normal, 12w, and 16w, showing severe synaptic loss in the
strata of the CA1 and dentate gyrus, but preservation of the DG -> CA3 projection. [DeF] Higher power pictures of these
strata, used for quantiﬁcation in the hippocampus (M) according to the equation Tcc L Trad/Tcc L TCtx (GeI; see
Supplementary Methods; available online) 10x pictures of the thalamus at approximately bregma L2.5 (AP), showing
the external medullary lamina (eml), ventroposterior nucleus (VP) and the posterior nucleus (Po) and clear synaptic
loss in the VP at 16 weeks. [JeL] Higher power pictures of these areas, used for quantiﬁcation of thalamic synaptic
density according to the equation TemlL TVP/TemlL TPo (N; see Supplementary Methods; available online) and % sy38-
positive area within the eml (O). Pairwise comparisons to ME7 12 week animals by Bonferroni post-hoc tests after
signiﬁcant main effect of disease stage by one-way ANOVA. *p <0.05, ***p <0.001.
Davis et al.Neuropathological Changes Underpinning Increased
Risk. Synaptic loss is a strong correlate of cognitive
decline in dementia.24,25 Synaptic density in the hip-
pocampus (Fig. 4AeC and, higher power, DeF) de-
creases in prion-diseased mice at 12 weeks (Fig. 4B)
and 16 weeks (Fig. 4C) post-inoculation comparedAm J Geriatr Psychiatry 23:4, April 2015with normal mice (Fig. 4A). The ratio between den-
sity in the stratum radiatum and the neocortex is
shown in Figure 4M. Thus, synaptic integrity de-
creases with disease progression (one-way ANOVA,
effect of disease stage: F(2,16) ¼ 86.54, p <0.0001) with
signiﬁcantly lower synaptic density in 12w than NBH409
FIGURE 5. Axonal pathology in animals at 16 weeks of disease
progression. Formalin ﬁxed, parafﬁn-embedded
brains from NBH and ME7 animals, 16 weeks post-
inoculation, were sectioned (10 mm) and labelled
with antibodies against synaptophysin (Sy38 [A,B]),
phosphorylated neuroﬁlament heavy chain (SMI-
31 [C,D]); unphosphorylated neuroﬁlament heavy
chain (SMI-32 [E,F]) and amyloid precursor protein
(APP695 [G,H]). Photograph with 10x objectives,
except [G,H]: photograph under 100x oil
immersion objective. Scale bar for [AeF] shown in
[F] [ 250 mm, and that in [H] serves for panels [G]
and [H] (25 mm). vp thal: ventroposterior thalamic
nucleus; eml: external medullary lamina.
Dementia Severity and Delirium Susceptibility(p <0.001), and a smaller further decrease at 16w
(p <0.05).
There was signiﬁcant thalamic synaptic loss in ME7
mice, particularly in the ventroposterior nuclei when
compared with the posterior nucleus. Regarding the
synaptic density ratio between these two structures
(4n), a one-way ANOVA showed an effect of disease
stage (F(2,19)¼ 45.75, p<0.0001). This synaptic losswas
relatively mild at 12w (12w versus NBH, p <0.05;
Fig. 4H), but signiﬁcantly worse at 16w than at 12w
(p <0.001; Fig. 4I). Furthermore, in 16w ME7 animals
the external medullary lamina, an interthalamic white
matter tract, showed many large spheroidal synapto-
physin deposits (Fig. 4I), representing signiﬁcant
axonal/white matter pathology. One-way ANOVA
(Fig. 4O) showed a main effect of disease stage
(F(2,19) ¼ 24.12, p <0.0001) and signiﬁcant increase at
16w with respect to both NBH and 12w animals
(p <0.001). This axonal pathology was not present at
12w. Similar white matter synaptophysin deposits
were observed in the ﬁmbria (axons from basal fore-
brain cholinergic areas to the hippocampus), and in the
internal capsule (thalamic output to the cortical
mantle) (Supplementary Fig. 2; available online).
Therefore, susceptibility to robust cognitive dysfunc-
tion associates with the spread of pathology to the
thalamus and to multiple white matter tracts.
Because altered axon morphology shows strong
correlation with dementia status,26 we sought further
evidence for axonal pathology in 16w ME7 animals.
We labeled the thalamus with antibodies for axonal
pathology (Fig. 5) in NBH and ME7 16w animals.
Synaptic element accumulation in the external med-
ullary lamina white matter (Fig. 5B) was associated
with discontinuity of axons (Fig. 5D), loss of elon-
gated neuroﬁlament labeling and the appearance of
spheroids/varicosities (Fig. 5F). Axonal pathology
was also demonstrated by APP-positive axonal
spheroids in the external medullary lamina (Fig. 5H).
Thus, there were graded levels of synaptic and
axonal pathology in ME7 animals, with the relation-
ship 16w > 12w > NBH.DISCUSSION
This study has demonstrated a strong association
between severity of existing cognitive impairment
and future delirium risk in a true population-based410sample of older humans, recapitulated in a mouse
model of acute and ﬂuctuating cognitive dysfunction.
Prior Cognitive Impairment as a Risk Factor for
Delirium
It is established that dementia or prior cognitive
impairment is a signiﬁcant risk factor for delirium.8Am J Geriatr Psychiatry 23:4, April 2015
Davis et al.This risk factor has typically been dichotomized,
however, such that patients are designated either
cognitively impaired or cognitively normal. A
strength of the current study is that subjects were
assessed in respect of a continuum of cognitive
function (in the case of humans) or graded categories
of neurodegenerative pathology (in the case of mice).
Both data sets demonstrate increasing susceptibility to
acute deﬁcits with increasing underlying cognitive or
neurodegenerative pathology, providing empirical
human and animal evidence that dementia-associated
risk is not binary but rather is on a continuum. The
use of MMSE rather than more comprehensive
cognitive testing was a limitation, although scores
were normally distributed and no ceiling effect was
observed. Retrospective delirium ascertainment in
Vantaa 85þ is a further limitation of the study. This is
mitigated to an extent, however, by corroboration
from multiple sources including hospital and primary
care notes. Medical records have been validated for
the diagnosis of delirium history,27 and the diagnostic
accuracy for past episodes is likely to be higher if case
notes are reviewed in conjunction with clinical inter-
view, as is the case here. Missing data on MMSE at
baseline was informative; here it was associated with
higher delirium risk. This is consistent with other
observations that inability to complete cognitive
testing is associated with poorer outcomes.28,29 That
the comorbidity burden does not appear to be
signiﬁcantly associated with delirium risk is in keep-
ing with data showing that the association between
delirium and adverse outcomes is over and above that
expected for comorbidity burden alone.30 Neverthe-
less, it is difﬁcult to be deﬁnitive here as the present
analysis lacks power to fully explore the effects of
frailty and comorbidity on delirium and dementia.Reﬁnement and Validation of a Mouse Model of
Delirium During Dementia
For the ﬁrst time in any animal model of neuro-
degeneration, we have demonstrated progressively
increased risk of acute cognitive dysfunction upon
application of a standardized systemic inﬂammatory
insult in animals with advancing synaptic and white
matter pathology. Applying DSM-IV criteria for
delirium, the mouse model demonstrated an acute
onset, ﬂuctuating, change in cognition not better
accounted for by dementia, induced by LPS (aAm J Geriatr Psychiatry 23:4, April 2015reasonable mimic of a general medical condition
effecting physiological disturbance). The nature of
cognitive/attentional impairment requires discussion.
The T-maze task used here relies on working mem-
ory31 and an ability to focus and shift attention be-
tween arms of the maze. Performance is proposed to
reﬂect short-term reduction in attention to recently
visited spatial locations.21,22 Thus animals either fail
to attend to the location they are currently visiting on
the sample run, or fail to remember or habituate to
that location just 25 seconds later. This study is also
the ﬁrst, to our knowledge, to demonstrate ﬂuctu-
ating course in inﬂammation-induced cognitive
dysfunction. In addition, LPS-treated ME7 animals
show exaggerated hypoactivity (psychomotor distur-
bance), signiﬁcantly reduced interaction with their
environment (Supplementary Video 1; available on-
line) and impaired acquisition of new spatial mem-
ories in a visuospatial Y-maze escape task,32 but
preservation of long-term visuospatial memory if ac-
quired prior to LPS treatment. These data, therefore,
show psychomotor disturbance and ﬂuctuating
impairment of dynamic cognitive processes and may
be consistent with human delirium data showing
impairments on cognitive tasks involving online
processing of novel, trial speciﬁc, information but
preservation of previously acquired long-term mem-
ories.33 We believe that the dysfunction occurring in
this mouse model may fulﬁll the DSM-IV criteria
adequately (Table 1) and given the constraints of
examining cognitive function in markedly hypoactive
animals, this T-maze task is appropriate for interro-
gating an individual’s ability to attend to and process
cues from its environment to inform behavior. Our
results are also consistent with recent data showing
impaired reversal learning and attention after sys-
temic inﬂammatory insult.34
The current mouse model mirrors the human
epidemiological ﬁnding that greater severity of dis-
ease confers progressively increased risk for delirium.
This represents a signiﬁcant validation of this animal
model, indicating that it has predictive value and
reinforcing the impetus to use ﬁndings arising from
this model to explore aspects of delirium patho-
physiology. It is important to stress that heteroge-
neous clinical presentations cannot be modeled by a
single experimental system. The model recapitulates
hypoactivity, altered arousal and ﬂuctuating cogni-
tive deﬁcits in domains relevant to delirium and as411
Dementia Severity and Delirium Susceptibilitysuch addresses aspects of hypoactive delirium trig-
gered by systemic inﬂammation superimposed on
existing dementia. Generalizations beyond this
should be treated cautiously.Delirium Pathophysiology
We demonstrated an effect of severity of neuropa-
thology on risk of acute and ﬂuctuating cognitive def-
icits. The neuropathological features shown here may
be directly relevant to delirium pathophysiology.
Although the neuroanatomy of escape-from-water T-
maze alternation has been little studied, the hippo-
campus is undoubtedly, but not exclusively, involved:
there is evidence also for prefrontal cortex, thalamus,
and amygdala involvement in impaired spontaneous
alternation.35e38 Robust white matter pathology in the
ﬁmbria (Supplementary Data; available online), which
connects the septum to the hippocampus, and disrup-
tion in this T-maze by muscarinic cholinergic receptor
antagonism (scopolamine)39 suggest roles for the sep-
tohippocampal pathway and cholinergic neurons,
although robust cognitive dysfunction was more
strongly associated with thalamic ventroposter-
omedial synaptic and white matter pathology (at 16
weeks). The thalamus processes sensory information
before output to the cortex via the internal capsule,
which is also pathologically affected here
(Supplementary Data; available online), and thalamic
ischemic lesions are also reportedly associated with
delirium.40,41 Furthermore key arousal centers of the
brain, the locus coeruleus noradrenergic andbrainstem
acetylcholinergic neurons, have opposite effects on
spontaneous activity in the ventroposteromedial thal-
amus in rodents42 with corresponding effects on
arousal (cortical activation and deactivation respec-
tively).43 Thus, thalamic pathologymight underpin the
markedly suppressed arousal observed in ME7þLPS
mice32 (Supplementary Video 1; available online) and
perhaps in humans. Although inattention is a core
feature of delirium and requires frontal and parietal
cortex communication,44 this cannot occur without
sufﬁcient arousal, which is generated in sub-cortical
structures.45 It has been reported that altered level of
arousal is a strong predictor of inattention and associ-
ates with human delirium.46 Therefore, it is possible
that sub-cortical structures affecting arousal have an
important role in hypoactive delirium. Speciﬁc evi-
dence for prior cortical pathology as a risk factor is412sparse and conﬂicting: Frontotemporal dementia and
early-onset Alzheimer disease (AD) constitute lesser
risk factors for delirium than more distributed pathol-
ogies like vascular dementia and late-onset AD,9 while
existing impairment in executive function, which is
frontal cortex dependent, selectively predisposes to
delirium.47,48 Clearly, the neuroanatomical basis of
increased delirium risk requires more research.
The progressive loss of presynaptic terminals and
the accumulation of white matter pathology shown
here represent signiﬁcant brain disconnectivity and
quantiﬁable loss of “brain reserve”.49 Synaptic loss is
a strong correlate of cognitive decline50 and neuronal
pathology occurs many years before cognitive
impairment in AD.51 The mouse data suggest that
prior degenerative pathology increases risk for acute
cognitive impairment even before baseline cognitive
impairment has emerged and we propose that syn-
aptic loss will predict susceptibility to delirium in
humans. Interestingly, in healthy volunteer experi-
ments acute systemic inﬂammation did not affect
performance on the Stroop test of sustained attention/
executive function but successful performance under
systemic inﬂammation recruited signiﬁcantly more
distributed brain areas.52 Recruitment of additional
brain areas during systemic inﬂammation will likely
be hindered by synaptic and axonal pathology such as
that demonstrated in the current study and we hy-
pothesize that existing synaptic loss is a major pre-
disposing factor for the precipitation of delirium by
mild/moderate infection in advanced age/dementia.
Although synaptic disconnection may be a major
contributor to delirium risk, other aspects of dementia,
such as microglial activation and chronic hypo-
cholinergic function, are also likely to play signiﬁcant
roles. Both cyclooxygenase-1 inhibition and IL-1 recep-
tor antagonist are protective in this model.53 Simi-
larly, cholinergic lesions increase susceptibility to
inﬂammation-induced cognitive deﬁcits39 and there is
evidence that acetylcholinergic tone modulates inﬂam-
matory responses both centrally and peripherally.54,55
Finally, delirium increases the risk of subsequent
dementia,13,56,57 but the current data suggest that
delirium unmasks an underlying neurodegenerative
process rather than creates this neuropathology
outright. The acute deﬁcits triggered in this studywere
reversible and did not cause additional loss of synaptic
terminals but LPS challenges have been deliberately
mild here to facilitate cognitive testing. SigniﬁcantlyAm J Geriatr Psychiatry 23:4, April 2015
Davis et al.higher LPS doses do induce signiﬁcant new pathology
and alter disease-associated decline58e61 consistent
with observations in the Vantaa 85þ cohort.13CONCLUSION
The current data represent the clearest empirical
demonstration that greater degrees of neurodegene-
ration at baseline increase the risk, duration, and
severity of delirium. They support the established
predisposing/precipitating factor model of
delirium,62 and answer recent calls to elucidate pre-
disposing factors further.8,63,64 We hypothesize that
the axonal and synaptic pathology shown here
constitute key factors contributing to the overall
frailty of brain function and may underpin the failure
of the degenerating brain to demonstrate resilience
upon “stress-testing” with systemic inﬂammation.
Epidemiological, experimental, and clinical efforts are
vital to identify prevention andmanagement strategiesAm J Geriatr Psychiatry 23:4, April 2015of this common, distressing, and serious condition.
Animal models may well have utility in unraveling
molecular mechanisms.
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